All manufacturers Aburaihan Alchemia Pharma Alpha Pharma Anhui Anke Biotechnology Arcas Nutrition Axio Labs Balkan Pharmaceuticals Bayer Bio-Peptide Biochem Bioniche Pharma Bioreaktor Biosira BM Pharmaceuticals Body Research British Dispensary British Dragon Canada Peptides Centurion Laboratories Cooper Desma Diamond Dynamic Labs Eifelfango Euro PharmLabs Excel Pharma Galenika Gen Shi Lab GeneScience Genesis GEP Hilma Biocare Iran Hormone Jelfa Jinan Pharmaceuticals Kohoh Pharma Kubera Pharma Lilly Magnus Pharmaceuticals Malay Tiger Norma Nouveaux Novo Nordisk Novosarm Onyx Organon Pfizer Pharmacom Phoenix Primus Ray Lab QPharma Royal Pharma Sandoz Sci Pharma Tech Shree Venkatesh SIS Labs SP Labarotories Sport Pharma Swiss Remedies Titan Vermodje West Pharm ZPHC
Somatuline® Depot (lanreotide – Ipsen Biopharmaceuticals) was granted a new indication on Sept. 18, 2017. The long-acting somatostatin analog, first approved in 2007 to treat acromegaly, is now indicated for treating adult carcinoid syndrome. Acromegaly includes uncontrolled growth of the face, feet and hands caused by excess growth hormone secretion; carcinoid syndrome is due to over production of serotonin and other substances that results in breathing problems, diarrhea, fast heartbeats and skin reactions such as flushing. Somatuline Depot also is approved for treating neuroendocrine tumors of the gastro-entero-pancreatic system (GEP-NETs). Administered by a healthcare professional as deep subcutaneous (SC) injections once every four weeks, doses vary depending on the condition being treated. Updated prescribing information is available here .